Rowlandmiller & Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Rowlandmiller & Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$105K	Buy	+3,085	New	+$103K	0.02%	192

Other funds holding TEVA

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

AIIMS

Analyst IMS Investment Management Services Tel-Aviv, Israel $4.3B AUM 37.33% 1-Year Est. Return

UBP

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

PMG

Private Management Group Irvine, California $3.8B AUM 23.19% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Rowlandmiller & Partners's TEVA Position: Q2 2026 in Review

Rowlandmiller & Partners opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 3,085 shares worth $105K. The stake represents 0.02% of the portfolio and ranks #192 among its holdings.

232 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Rowlandmiller & Partners held 3,085 shares of Teva Pharmaceuticals worth $105K as of Q2 2026.
Teva Pharmaceuticals was a new Rowlandmiller & Partners position in Q2 2026.
Teva Pharmaceuticals made up 0.02% of Rowlandmiller & Partners's portfolio in Q2 2026, its #192 holding.
232 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Rowlandmiller & Partners's 13F filing for Q2 2026, filed 23 Jul 2026.